S&P 500
(1.02%) 5 099.96 points

Dow Jones
(0.40%) 38 240 points

Nasdaq
(2.03%) 15 928 points

Oil
(0.11%) $83.66

Gas
(-3.32%) $1.920

Gold
(0.30%) $2 349.60

Silver
(-0.43%) $27.52

Platinum
(0.42%) $924.40

USD/EUR
(0.32%) $0.935

USD/NOK
(0.67%) $11.02

USD/GBP
(0.13%) $0.800

USD/RUB
(-0.07%) $92.11

Realtime updates for Nektar Therapeutics [NKTR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Last Updated26 Apr 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

0.00% $ 1.320

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...

Stats
Today's Volume	558 779
Average Volume	2.52M
Market Cap	242.38M
EPS	$0 ( 2024-03-04 )
Next earnings date	( $-0.200 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.910
ATR14	$0.00300 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Deep Track Capital, Lp	Buy	0	Common Stock
2024-02-20	Zalevsky Jonathan	Sell	9 014	Common Stock
2024-02-20	Wilson Mark Andrew	Sell	7 606	Common Stock
2024-02-20	Robin Howard W	Sell	20 033	Common Stock
2023-12-13	Zalevsky Jonathan	Buy	250 000	Stock Option

INSIDER POWER
84.96
Last 97 transactions
Buy: 6 976 063 \| Sell: 637 451

Volume Correlation

Long: 0.50 (weak)

Short: 0.86 (strong)

Signal:(65.532) Same movement expected

Nektar Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nektar Therapeutics Correlation - Currency/Commodity

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

-0.04
( neutral )

Nektar Therapeutics Financials

Annual	2023
Revenue:	$90.12M
Gross Profit:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2023
Revenue:	$90.12M
Gross Profit:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2022
Revenue:	$92.06M
Gross Profit:	$70.42M (76.50 %)
EPS:	$-1.970

FY	2021
Revenue:	$101.91M
Gross Profit:	$77.01M (75.57 %)
EPS:	$-2.86

Financial Reports:

No articles found.

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.